[Effective concentration and dosage for cardiac glycosides].

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Weiss M; Förster W
  • Source:
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete [Z Gesamte Inn Med] 1980 Jan 01; Vol. 35 (1), pp. 1-7.
  • Publication Type:
    English Abstract; Journal Article; Review
  • Language:
    German
  • Additional Information
    • Transliterated Title:
      Wirkkonstanten und Dosierung von Herzglykosiden.
    • Source:
      Publisher: Georg Thieme Country of Publication: Germany NLM ID: 21730470R Publication Model: Print Cited Medium: Print ISSN: 0044-2542 (Print) Linking ISSN: 00442542 NLM ISO Abbreviation: Z Gesamte Inn Med Subsets: MEDLINE
    • Publication Information:
      Original Publication: Leipzig : Georg Thieme, [1946]-c1993.
    • Subject Terms:
      Cardiac Glycosides/*administration & dosage; Biological Availability ; Biopharmaceutics ; Cardiac Glycosides/blood ; Cardiac Glycosides/metabolism ; Digitoxin/pharmacology ; Digoxin/pharmacology ; Humans ; Strophanthins/pharmacology ; Time Factors
    • Abstract:
      The pharmacokinetic fundaments of the glycoside therapy with strophanthin, digoxin and digitoxin are described and compared with the traditional clinically oriented parameters total body stores, decay ratio and so on. Newly introduced is the parameter medium remaining duration in the circulation. A critical analysis of the hitherto cited values of the total body stores and the decay ratio established from the clinical effect shows that on the basis of pharmacokinetic calculations the corresponding values for digoxin and digotoxin need a great correction. The fully active quantity for digoxin lies between 0.5 and 0.8 mg and the subsiding share is 50%. The values for digitoxin lie at 0.9 mg and 9%. Furthermore the causes of the interindividual variability of the maintenance dose are discussed. According to the already existing international experiences an essential improvement of the therapy is possible, when the pharmacokinetically established effective constants are taken into consideration. Examinations of the inter- and intraindividual differences in the kinetics of the glycosides and the development of digoxin preparations with a high (i.e. constant) bioavailability may contribute to a further decrease of the frequency of toxic side-effects in future.
    • Number of References:
      48
    • Accession Number:
      0 (Cardiac Glycosides)
      0 (Strophanthins)
      73K4184T59 (Digoxin)
      E90NZP2L9U (Digitoxin)
    • Publication Date:
      Date Created: 19800101 Date Completed: 19801021 Latest Revision: 20131121
    • Publication Date:
      20231215
    • Accession Number:
      6996345